| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lorenzo Barba, Lorenzo Gaetani, Silvia Sperandei, Elena Di Sabatino, Samir Abu-Rumeileh, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Lucilla Parnetti, Massimiliano Di FIlippo, Markus Ott. CSF synaptic biomarkers and cognitive impairment in multiple sclerosis. Journal of neurology. vol 272. issue 1. 2024-12-21. PMID:39708160. |
people with multiple sclerosis (pwms) experience various degrees of cognitive impairment (ci). |
2024-12-21 |
2024-12-24 |
Not clear |
| Zachary Leibovit-Reiben, Hannah Godfrey, Patrick Jedlowski, Rebecca Thied. Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Melanoma research. 2024-12-10. PMID:39656586. |
several novel associations were identified; including epidural lipomatosis (ror: 320.07, 95% ci: 123.76-827.77 for v + c), peripheral nerve lesion (ror: 185.64, 95% ci: 73.95-466.03 for v + c), guillain-barre syndrome (rors: 8.80, 2.94, and 11.79, 95% cis: 3.65-21.22, 1.40-6.19, and 5.87-23.66 for v + c, d + t, and e + b), demyelinating polyneuropathy (rors: 24.72 and 78.98, 95% ci: 8.16-74.86 and 24.84-251.13 for d + t and e + b), and multiple sclerosis (ror: 5.90, 95% ci: 3.06-11.40 for d + t) in melanoma patients. |
2024-12-10 |
2024-12-21 |
Not clear |
| Alireza Kooshki, Reyhane Farmani, Alireza Amirabadizadeh, Omid Mehrpour, Mohammad Javad Sanjari, Samaneh Nakhae. Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PloS one. vol 19. issue 12. 2024-12-06. PMID:39642137. |
results from the pooled data, analyzed using a random-effects model, revealed higher levels of as (hedge's g = 4.00 μg/l, 95% ci = 2.03 to 5.98, p <0.001; i2 = 97.69%, p<0.001) and cd (hedge's g = 1.20 μg/l, 95% ci = 0.13 to 2.27, p = 0.028; i2 = 97.99%, p<0.001) in multiple sclerosis patients compared to healthy ones. |
2024-12-06 |
2024-12-09 |
human |
| Abdorreza Naser Moghadasi, Omid Mirmosayyeb, Sara Bagherieh, Mohammad Ali Sahraian, Mahsa Ghajarzade. Computerized cognitive rehabilitation in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Caspian journal of internal medicine. vol 16. issue 1. 2024-12-02. PMID:39619744. |
cognitive impairment (ci) is one of the main features of multiple sclerosis (ms). |
2024-12-02 |
2024-12-06 |
Not clear |
| Chunyi Lyu, Yan Wang, Ruirong X. Mendelian randomization analysis reveals causal effects of inflammatory bowel disease and autoimmune hyperthyroidism on diffuse large B-cell lymphoma risk. Scientific reports. vol 14. issue 1. 2024-11-26. PMID:39587169. |
the ivw results revealed no associations between the other seven ads and dlbcl: asthma (or = 0.782, 95% ci 0.395-1.546, p = 0.159), psoriasis (or = 0.842, 95% ci 0.669-1.060, p = 0.143), type 1 diabetes (or = 1.071, 95% ci 0.860-1.334, p = 0.537), multiple sclerosis (or = 1.331, 95% ci 0.941-1.883, p = 0.105), sarcoidosis (or = 1.324, 95% ci 0.861-2.038, p = 0.200), ankylosing spondylitis (or = 1.884, 95% ci 0.776-4.573, p = 0.161), and celiac disease (or = 1.003, 95% ci 0.854-1.178, p = 0.969). |
2024-11-26 |
2024-11-28 |
Not clear |
| Zachary L Weinstock, Ralph H B Benedic. Cognitive Relapse in Multiple Sclerosis: New Findings and Directions for Future Research. NeuroSci. vol 3. issue 3. 2024-11-01. PMID:39483431. |
multiple sclerosis (ms) is a chronic inflammatory, demyelinating disease of the central nervous system, often presenting with brain atrophy and cognitive impairment (ci). |
2024-11-01 |
2024-11-03 |
Not clear |
| Michela Bossa, Nicola Manocchio, Ornella Argent. Non-Pharmacological Treatments of Cognitive Impairment in Multiple Sclerosis: A Review. NeuroSci. vol 3. issue 3. 2024-11-01. PMID:39483435. |
cognitive impairment (ci) represents a common symptom in patients suffering from multiple sclerosis (ms), which can affect every stage of the disease course. |
2024-11-01 |
2024-11-03 |
Not clear |
| Emilio Portaccio, Maria Pia Amat. Cognitive Impairment in Multiple Sclerosis: An Update on Assessment and Management. NeuroSci. vol 3. issue 4. 2024-11-01. PMID:39483763. |
cognitive impairment (ci) is a core feature of multiple sclerosis (ms) and affects up to 65% of patients in every phase of the disease, having a deep impact on all aspects of patients' lives. |
2024-11-01 |
2024-11-03 |
Not clear |
| Nasim Rezaeimanesh, Naghme Abbasi Kasbi, Roghayyeh Saeedi, Mohammad Ali Sahraian, Soodeh Razeghi Jahromi, Abdorreza Naser Moghadas. Investigating the Correlation Between Cognitive Function and Fasting Blood Sugar, Fasting Insulin Level and Insulin Sensitivity in Patients With Multiple Sclerosis. Endocrinology, diabetes & metabolism. vol 7. issue 6. 2024-10-07. PMID:39374429. |
there has been a surge in interest in identifying the factors that impact cognitive impairment (ci) in patients with multiple sclerosis (ms). |
2024-10-07 |
2024-10-10 |
Not clear |
| Gabriel de Deus Vieira, Fernanda Ferrão Antônio, Alfredo Damascen. Association between paramagnetic rim lesions with cognitive impairment in pediatric multiple sclerosis. Multiple sclerosis and related disorders. vol 91. 2024-09-14. PMID:39276597. |
pediatric onset multiple sclerosis (poms) patients are at risk for cognitive impairment (ci). |
2024-09-14 |
2024-09-18 |
Not clear |
| Jessica Podda, Federica Di Antonio, Andrea Tacchino, Ludovico Pedullà, Erica Grange, Mario Alberto Battaglia, Giampaolo Brichetto, Michela Ponzi. A taxonomy of cognitive phenotypes in Multiple Sclerosis: a 1-year longitudinal study. Scientific reports. vol 14. issue 1. 2024-09-02. PMID:39223279. |
since ci is highly variable in severity and progression, monitoring cognitive phenotypes over time may be useful to identify trajectory of cognitive decline in multiple sclerosis (ms). |
2024-09-02 |
2024-09-05 |
Not clear |
| Xiaohua Wang, Shangqing Liu, Zichun Yan, Feiyue Yin, Jinzhou Feng, Hao Liu, Yanbing Liu, Yongmei L. Radiomics Nomograms Based on Multi-sequence MRI for Identifying Cognitive Impairment and Predicting Cognitive Progression in Relapsing-Remitting Multiple Sclerosis. Academic radiology. 2024-08-28. PMID:39198138. |
to build radiomics nomograms based on multi-sequence mri to facilitate the identification of cognitive impairment (ci) and prediction of cognitive progression (cp) in patients with relapsing-remitting multiple sclerosis (rrms). |
2024-08-28 |
2024-09-01 |
Not clear |
| Stefano Ziccardi, Agnese Tamanti, Claudia Ruggieri, Maddalena Guandalini, Damiano Marastoni, Valentina Camera, Luigi Montibeller, Valentina Mazziotti, Stefania Rossi, Milena Calderone, Francesca Benedetta Pizzini, Stefania Montemezzi, Roberta Magliozzi, Massimiliano Calabres. CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage. Neurology(R) neuroimmunology & neuroinflammation. vol 11. issue 6. 2024-08-23. PMID:39178066. |
cognitive impairment (ci) in multiple sclerosis (ms) is frequent and determined by a complex interplay between inflammatory and neurodegenerative processes. |
2024-08-23 |
2024-08-26 |
Not clear |
| Pavel Hok, Quang Thong Thai, Barbora Rehák Bučková, Martin Domin, Kamila Řasová, Jaroslav Tintěra, Martin Lotze, Matthias Grothe, Jaroslav Hlink. Global functional connectivity reorganization reflects cognitive processing speed deficits and fatigue in multiple sclerosis. European journal of neurology. 2024-07-26. PMID:39058296. |
cognitive impairment (ci) in multiple sclerosis (ms) is associated with bidirectional changes in resting-state centrality measures. |
2024-07-26 |
2024-07-28 |
Not clear |
| Mozhde Askari, Omid Mirmosayyeb, Fatemeh Fattahi, Hamed Ghoshouni, Elham Moases Ghaffary, Vahid Shaygannejad, Mahsa Ghajarzade. Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Caspian journal of internal medicine. vol 15. issue 3. 2024-07-16. PMID:39011445. |
prevalence of cognitive impairment (ci) in patients with multiple sclerosis (ms): a systematic review and meta-analysis. |
2024-07-16 |
2024-07-18 |
Not clear |
| Mozhde Askari, Omid Mirmosayyeb, Fatemeh Fattahi, Hamed Ghoshouni, Elham Moases Ghaffary, Vahid Shaygannejad, Mahsa Ghajarzade. Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Caspian journal of internal medicine. vol 15. issue 3. 2024-07-16. PMID:39011445. |
one of the complications of multiple sclerosis (ms) is cognitive impairment (ci). |
2024-07-16 |
2024-07-18 |
Not clear |
| Dayoung Seo, Jeong Min So, Jiyon Kim, Heejae Jung, Inhye Jang, Hyunjin Kim, Dong-Wha Kang, Young-Min Lim, Jaesoon Choi, Eun-Jae Le. Digital symbol-digit modalities test with modified flexible protocols in patients with CNS demyelinating diseases. Scientific reports. vol 14. issue 1. 2024-06-26. PMID:38918552. |
cognitive impairment (ci) is prevalent in central nervous system demyelinating diseases, such as multiple sclerosis (ms) and neuromyelitis optica spectrum disorders (nmosd). |
2024-06-26 |
2024-06-29 |
Not clear |
| Eva A Krijnen, Rose-Marie Kouwenhoven, Samantha Noteboom, Frederik Barkhof, Bernard Mj Uitdehaag, Eric C Klawiter, Martijn D Steenwijk, Menno M Schoonheim, Ismail Koubiy. Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2024-06-14. PMID:38872276. |
cortical lesion subtypes' occurrence and distribution across networks may shed light on cognitive impairment (ci) in multiple sclerosis (ms). |
2024-06-14 |
2024-06-16 |
Not clear |
| Albert Aboseif, Moein Amin, James Bena, Kunio Nakamura, Gabrielle Macaron, Daniel Ontaned. Association Between Disease-Modifying Therapy and Information Processing Speed in Multiple Sclerosis. International journal of MS care. vol 26. issue 3. 2024-05-21. PMID:38765300. |
cognitive impairment (ci) is common in multiple sclerosis (ms). |
2024-05-21 |
2024-05-27 |
Not clear |
| Sana Mohammadi, Sadegh Ghaderi, Farzad Fateh. Putamen iron quantification in diseases with neurodegeneration: a meta-analysis of the quantitative susceptibility mapping technique. Brain imaging and behavior. 2024-05-17. PMID:38758278. |
relapsing-remitting multiple sclerosis (rrms) also showed increased putaminal iron at 0.37 (95% ci 0.177 to 0.58). |
2024-05-17 |
2024-05-27 |
Not clear |